These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16859391)

  • 21. Polycyclic cage structures as lipophilic scaffolds for neuroactive drugs.
    Joubert J; Geldenhuys WJ; Van der Schyf CJ; Oliver DW; Kruger HG; Govender T; Malan SF
    ChemMedChem; 2012 Mar; 7(3):375-84. PubMed ID: 22307951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacotherapeutical reduction of post-hypoxic-ischemic brain injury in the newborn.
    Peeters C; van Bel F
    Biol Neonate; 2001; 79(3-4):274-80. PubMed ID: 11275665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A molecular approach in drug development for Alzheimer's disease.
    Agatonovic-Kustrin S; Kettle C; Morton DW
    Biomed Pharmacother; 2018 Oct; 106():553-565. PubMed ID: 29990843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders.
    Naoi M; Maruyama W
    Curr Pharm Des; 2010; 16(25):2799-817. PubMed ID: 20698822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.
    Youdim MBH
    J Neural Transm (Vienna); 2018 Nov; 125(11):1719-1733. PubMed ID: 30341696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Latrepirdine: a systematic review of the preclinical studies].
    Cano-Cuenca N; Solís-García del Pozo J; Jordán J
    Rev Neurol; 2015 Jan; 60(1):35-42. PubMed ID: 25522862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron chelation and neuroprotection in neurodegenerative diseases.
    Li X; Jankovic J; Le W
    J Neural Transm (Vienna); 2011 Mar; 118(3):473-7. PubMed ID: 21161300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities.
    Zheng H; Youdim MB; Fridkin M
    ACS Chem Neurosci; 2010 Nov; 1(11):737-46. PubMed ID: 22778810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Mechanisms of action of Alzheimer medications].
    Alhainen K
    Duodecim; 2003; 119(20):1959-66. PubMed ID: 14640001
    [No Abstract]   [Full Text] [Related]  

  • 30. Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum.
    Tebano MT; Pintor A; Frank C; Domenici MR; Martire A; Pepponi R; Potenza RL; Grieco R; Popoli P
    J Neurosci Res; 2004 Jul; 77(1):100-7. PubMed ID: 15197743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent Developments in New Therapeutic Agents against Alzheimer and Parkinson Diseases: In-Silico Approaches.
    Cruz-Vicente P; Passarinha LA; Silvestre S; Gallardo E
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33920326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage.
    Mechlovich D; Amit T; Mandel SA; Bar-Am O; Bloch K; Vardi P; Youdim MB
    J Pharmacol Exp Ther; 2010 Jun; 333(3):874-82. PubMed ID: 20237072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [In vitro models for the study of nerve lesions and potential neuroprotective drugs].
    Abad-Santos F
    Rev Neurol; 1997 Dec; 25(148):2015-21. PubMed ID: 9528049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Curr Drug Targets; 2012 Apr; 13(4):483-94. PubMed ID: 22280345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Main Targets Involved in Neuroprotection for the Treatment of Alzheimer's Disease and Parkinson Disease.
    Gülcan HO; Orhan IE
    Curr Pharm Des; 2020; 26(4):509-516. PubMed ID: 32003681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deep eutectic solvent mediated synthesis of 3,4-dihydropyrimidin-2(1H)-ones and evaluation of biological activities targeting neurodegenerative disorders.
    Saleem Khan M; Asif Nawaz M; Jalil S; Rashid F; Hameed A; Asari A; Mohamad H; Ur Rehman A; Iftikhar M; Iqbal J; Al-Rashida M
    Bioorg Chem; 2022 Jan; 118():105457. PubMed ID: 34798458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons.
    Zheng H; Youdim MB; Weiner LM; Fridkin M
    Biochem Pharmacol; 2005 Nov; 70(11):1642-52. PubMed ID: 16226724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents.
    Zindo FT; Barber QR; Joubert J; Bergh JJ; Petzer JP; Malan SF
    Eur J Med Chem; 2014 Jun; 80():122-34. PubMed ID: 24769350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential therapeutic relevance of adenosine A2B and A2A receptors in the central nervous system.
    Popoli P; Pepponi R
    CNS Neurol Disord Drug Targets; 2012 Sep; 11(6):664-74. PubMed ID: 22963436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.